CS5005 / CStone Pharma - LARVOL DELTA

CStone Presents Preclinical Results of…CS5005 (SSTR2 ADC)…at 2025 AACR (PRNewswire) - "Key Highlights:...CS5005 demonstrated potent antigen-dependent cytotoxic activity against tumor cells in vitro and robust tumor-growth inhibition in CDX tumor model. The antitumor activity of CS5005 (SSTR2-DXd) is not compromised by concomitant ligand-derived treatments (e.g., octreotide, Lutathera), thereby avoiding drug-drug interference commonly observed with current anti-SSTR2 therapies. CS5005 demonstrated superior in vitro stability due to its proprietary linker, outperforming ADCs conjugated with well-validated dipeptide and tetrapeptide linkers."

Preclinical • Solid Tumor

CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studies (AACR 2025) - "In SCLC, SSTR2-targeted therapies, including RAZ101 (225Ac bearing RDC), PEN221 (peptide drug conjugate) etc., have shown encouraging clinical results. CS5005 represents a promising SSTR2-targeted ADC for the treatment of advanced solid tumors. The preclinical findings support further IND-enabling studies and clinical investigations of CS5005 as a novel therapeutical option."

Preclinical • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • SSTR • SSTR2

CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinical studies (PRNewswire) - "CStone to showcase...latest research achievements at AACR 2025....Abstract Number: 4751....Key Findings: CS5005 (SSTR2 ADC) demonstrated promising therapeutic potential by effectively killing tumor cells in both in vivo and in vitro studies, while maintaining a PK profile comparable to those of monoclonal antibodies. Additionally, a dual-target ADC against DLL3 and SSTR2 also exhibited potential as a therapeutic agent."

Preclinical • Oncology

CStone Reports 2024 Interim Results and Recent Corporate Updates (PRNewswire) - "Anticipated near-term catalysts include:...(i) CS2009: IND submissions expected in 2024/2025; (ii) CS5006: IND submission expected in 2025; (iii) CS5005: IND submission expected in 2025; (iv) CS2011/CS5007: IND submission expected in 2025."

IND • Solid Tumor

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates (CStone Pharma Press Release) - "(i) CS2009: submit clinical trial notification ('CTN') to Australian Human Research Ethics Committee ('HREC') by the end of 2024, and apply for China IND in the first quarter of 2025; (ii) CS5006: nominate PCC in the first half of 2024, and expect to file IND in 2025; (iii) CS5005: nominate PCC in 2024, and expect to file IND in 2025."

IND • New molecule • New trial • Solid Tumor